Sanofi-aventis (SNY) Announes FDA Approval of Multaq for Patients with Atrial Fibrillation or Atrial Flutter
More News related to SNY
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
- Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009
- Sanofi-aventis Video Q&A: CEO Chris Viehbacher Comments on Q3 '09 Earning and Outlook
Earlier today, Sanofi-aventis (NYSE: SNY) announced that the FDA has approved Multaq 400 mg Tablets for patients with atrial fibrillation (AF) or atrial flutter (AFL).
Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
Multaq is an anti-arrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted.
A U.S commercial launch planned for the summer of 2009.
Related Categories
FDAStocks Mentioned
-0.35Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
